Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
APGE
#1241
Apogee Therapeutics, Inc. Common Stock
70.000
0
+1.13%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+1.13%
Monthly Change
-3.86%
6 month change
+30.62%
Year Change
+30.62%
Previous Close
69.215
0
Open
70.000
0
Bid
Ask
Low
70.000
0
High
70.000
0
Volume
87
Markets
US Stock Market
Healthcare
APGE
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2023
2024
TTM
Key stats
Total common shares outstanding
37.17 M
46.02 M
—
Valuation ratios
Enterprise value
2.39 B
4.64 B
18.8 B
Price to earnings ratio
-8.49
-13.73
-43.62
Price to sales ratio
—
—
—
Price to cash flow ratio
9.53
14.6
46.87
Price to book ratio
1.14
1.88
3.15
Enterprise value to EBITDA ratio
—
—
—
Profitability ratios
Return on assets %
0.21
0.24
0.37
Return on equity %
0.13
0.14
0.18
Return on invested capital %
9 082.32
749.15
659.79
Gross margin %
—
—
—
Operating margin %
—
—
—
EBITDA margin %
—
—
—
Net margin %
—
—
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
19.38
18.55
66.59
Inventory turnover
—
—
—
Asset turnover
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
2.99
3.1
4.05
EBIT per share
—
—
—
EBITDA per share
—
—
—
Total debt per share
—
—
—
Cash per share
15.81
9.43
35.88
Net current asset value per share
15.93
9.6
36.58
Tangible book value per share
25.09
24.07
100.02
Working capital per share
15.11
9.08
34.38
Book value per share
25.09
24.07
100.02
News
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns
Intel, Iris Energy among market cap stock movers on Friday
Intel and AMD among market cap stock movers on Friday
Thursday’s Insider Activity: GameStop CEO’s $21M Buy Stands Out
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns
Top US Biopharma Stocks Poised for Growth in 2026, According to Deutsche Bank
Apogee Therapeutics CEO Henderson sells $1.6m in stock
Apogee Therapeutics stock hits all-time high at 81.0 USD
Regeneron announcements validate Apogee thesis, says Stifel
Apogee Therapeutics CMO sells $1.45 million in shares
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target